Data protection Impressum

Oncology

Western Switzerland is rapidly becoming a hotspot for biomanufacturing and life sciences companies, thanks to its strong infrastructure, skilled talent, and business-friendly policies. Yassin Nahi, GGBa (Greater Geneva Bern area) Life Science Director, shares how the region's research hubs, academic institutions, and regulatory support make it an ideal location for companies in this sector.

Why Switzerland

Why Western Switzerland for Biomanufacturing and Life Sciences Companies: an interview with expert Yassin Nahi

Hedera Dx has secured EUR 15 million to expand hospital-based cancer diagnostics, making precision oncology more accessible to patients worldwide.

Hedera Dx raises EUR 15 million to expand access to precision cancer care

27 May 2025

Swiss Medical Network has become the first healthcare provider in Western Europe to join the prestigious Mayo Clinic Care Network. The collaboration strengthens Switzerland’s position as a hub for advanced medical innovation and international clinical partnerships.

Swiss Medical Network joins Mayo Clinic Care Network to elevate patient care

13 May 2025

HAYA Therapeutics, a precision medicine company based at Biopôle in Lausanne, has closed a USD 65 million Series A funding round to accelerate the clinical development of its RNA-guided therapies and expand its regulatory genome platform.

HAYA Therapeutics raises USD 65 million to advance RNA-guided therapies for chronic disease

12 May 2025

A collaborative research team from EPFL, the University of Geneva (UNIGE), and Geneva University Hospitals (HUG) has been awarded the 2025 Leenaards Science Prize for a pioneering project aimed at enhancing the effectiveness of immunotherapy by altering the mechanical properties of cancer cells.

Western Switzerland research teams explore new strategy to boost cancer immunotherapy

14 April 2025

Medtech start-up Novigenix has received EUR 1.8 million from the EU’s Innovative Health Initiative to support the industrialization of its AI-driven liquid biopsy platform as part of a major international cancer research collaboration.

Novigenix secures EUR 1.8 million to scale precision oncology platform

9 April 2025

TheraMe!, a Lausanne-based medtech, is transforming cancer treatment by partnering with CSEM to develop an automated, microfluidic-based instrument. This breakthrough technology enables personalized drug screening on live tumor samples, providing cancer patients with tailored therapy recommendations before treatment begins.

CSEM and TheraMe! transform cancer therapy with personalized drug screening technology

28 January 2025

Limula, Actival, and AirCurve have received funding from the FIT to advance groundbreaking solutions in cell therapy production, dental health, and tracheal intubation. Limula secured a CHF 500,000 Tech Growth loan, while Actival and AirCurve each received CHF 100,000 Tech Seed loans.

Western Switzerland healthcare start-ups Limula, Actival, and AirCurve secure FIT funding

16 December 2024

Lymphatica Medtech, a Lausanne-based clinical-stage company specializing in innovative treatments for lymphedema, has raised EUR 17.9 million in a Series B funding round.

Lymphatica Medtech secures EUR 17.9 million to advance lymphedema treatment

15 October 2024

HAYA Therapeutics has announced a multi-year collaboration with Eli Lilly, potentially earning up to USD 1 billion in milestone payments to advance RNA-guided therapies for obesity and metabolic disorders.

HAYA Therapteutics enters major collaboration to advance RNA-based drug discovery

17 September 2024

1 2 3 4 5 … 8